RS20060004A - Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors - Google Patents

Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors

Info

Publication number
RS20060004A
RS20060004A YUP-2006/0004A YUP20060004A RS20060004A RS 20060004 A RS20060004 A RS 20060004A YU P20060004 A YUP20060004 A YU P20060004A RS 20060004 A RS20060004 A RS 20060004A
Authority
RS
Serbia
Prior art keywords
pyrrolo
pyrazole derivatives
kinase inhibitors
derivatives active
active
Prior art date
Application number
YUP-2006/0004A
Other languages
English (en)
Inventor
Mario Varasi
Daniele Fancelli
Barbara Forte
Jurgen Moll
Paola Vianello
Original Assignee
Pharmacia Italia S.P.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A., filed Critical Pharmacia Italia S.P.A.,
Publication of RS20060004A publication Critical patent/RS20060004A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Opisani su pirolo[3,4-c ]pirazolo derivati formule (I) i njihove farmaceutski prihvatljive soli, kao što je definisano u specifikaciju, procesi za njihovu pripremu i farmaceutski preparati koji ih sadrže; jedinjenja pronalaska su mogu koristiti, u terapiji, u lečenju oboljenja koja su povezana sa nepravilnom aktivnošću protein kinaze, kao što je kancer
YUP-2006/0004A 2003-07-09 2004-07-08 Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors RS20060004A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48581403P 2003-07-09 2003-07-09
PCT/EP2004/007515 WO2005005427A1 (en) 2003-07-09 2004-07-08 PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
RS20060004A true RS20060004A (en) 2008-06-05

Family

ID=34062099

Family Applications (2)

Application Number Title Priority Date Filing Date
YUP-2006/0004A RS20060004A (en) 2003-07-09 2004-07-08 Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors
RS20060004A RS52155B (sr) 2003-07-09 2004-07-08 DERIVATI PIROLO(3,4-c)PIRAZOLA AKTIVNI KAO INHIBITORI KINAZE

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20060004A RS52155B (sr) 2003-07-09 2004-07-08 DERIVATI PIROLO(3,4-c)PIRAZOLA AKTIVNI KAO INHIBITORI KINAZE

Country Status (42)

Country Link
US (2) US7141568B2 (sr)
EP (1) EP1644376B1 (sr)
JP (1) JP4728232B2 (sr)
KR (1) KR101075711B1 (sr)
CN (1) CN100564380C (sr)
AP (1) AP2214A (sr)
AR (1) AR050045A1 (sr)
AT (1) ATE480540T1 (sr)
AU (1) AU2004255347B2 (sr)
BR (1) BRPI0411868B8 (sr)
CA (1) CA2531759C (sr)
CR (1) CR8171A (sr)
CY (1) CY1110832T1 (sr)
DE (1) DE602004029045D1 (sr)
DK (1) DK1644376T3 (sr)
DO (1) DOP2004000949A (sr)
EA (1) EA009462B1 (sr)
EC (1) ECSP056246A (sr)
ES (1) ES2349780T3 (sr)
GE (1) GEP20084395B (sr)
GT (2) GT200400133A (sr)
HK (1) HK1089769A1 (sr)
HN (1) HN2004000232A (sr)
IL (1) IL172923A (sr)
IS (1) IS2843B (sr)
MA (1) MA28064A1 (sr)
ME (1) MEP51908A (sr)
MX (1) MXPA06000362A (sr)
MY (1) MY139072A (sr)
NO (1) NO332361B1 (sr)
NZ (1) NZ544514A (sr)
PA (1) PA8606201A1 (sr)
PE (1) PE20050325A1 (sr)
PL (1) PL1644376T3 (sr)
PT (1) PT1644376E (sr)
RS (2) RS20060004A (sr)
SI (1) SI1644376T1 (sr)
TN (1) TNSN06009A1 (sr)
TW (1) TWI343382B (sr)
UA (1) UA81682C2 (sr)
WO (1) WO2005005427A1 (sr)
ZA (1) ZA200600095B (sr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006381B1 (ru) * 2000-08-10 2005-12-29 Фармация Италия С.П.А. Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
CA2539549A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
CA2593428C (en) * 2005-01-10 2012-04-17 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200808311A (en) 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
ATE479432T1 (de) * 2006-11-03 2010-09-15 Nerviano Medical Sciences Srl Verfahren zur verabreichung einer antitumoralen verbindung
AR071780A1 (es) 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
CN102105148B (zh) * 2008-07-24 2013-04-10 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
US20110117212A1 (en) * 2008-07-24 2011-05-19 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
US20100022553A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
JP5738196B2 (ja) 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
WO2013088257A1 (en) 2011-12-12 2013-06-20 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
CA2953177C (en) 2014-06-23 2019-07-23 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
RU2765718C1 (ru) * 2015-06-15 2022-02-02 Убе Индастриз, Лтд. Замещенное производное дигидропирролопиразола
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717380B1 (fr) * 1994-03-15 1996-04-26 Oreal Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) * 1999-07-09 2001-01-11 Basf Ag Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
YU9602A (sh) 1999-08-12 2004-11-25 Pharmacia Italia S.P.A. Derivati 3(5)-amino-pirazola, postupak za njihovu izradu i njihova upotreba kao antitumornih agenasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EA006381B1 (ru) 2000-08-10 2005-12-29 Фармация Италия С.П.А. Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
NZ525892A (en) 2000-11-27 2004-11-26 Pharmacia Italia S Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof
MXPA03006478A (es) 2001-01-26 2003-09-22 Pharmacia Italia Spa Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales.
EP1820503B1 (en) 2001-09-26 2012-02-22 Pfizer Italia S.r.l. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
US20060100233A1 (en) 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
GT200400133AA (es) 2007-07-10
RS52155B (sr) 2012-08-31
TNSN06009A1 (fr) 2007-10-03
AR050045A1 (es) 2006-09-27
EP1644376A1 (en) 2006-04-12
JP4728232B2 (ja) 2011-07-20
ATE480540T1 (de) 2010-09-15
TWI343382B (en) 2011-06-11
BRPI0411868B8 (pt) 2021-05-25
PE20050325A1 (es) 2005-05-17
NO332361B1 (no) 2012-09-03
PA8606201A1 (es) 2005-08-04
MXPA06000362A (es) 2006-03-28
IL172923A (en) 2011-09-27
CY1110832T1 (el) 2015-06-10
US20060276471A1 (en) 2006-12-07
KR20060033001A (ko) 2006-04-18
AU2004255347A1 (en) 2005-01-20
KR101075711B1 (ko) 2011-10-21
MEP51908A (en) 2011-05-10
EP1644376B1 (en) 2010-09-08
CA2531759C (en) 2013-04-02
NZ544514A (en) 2009-07-31
DE602004029045D1 (de) 2010-10-21
US7582628B2 (en) 2009-09-01
DK1644376T3 (da) 2011-01-03
CN100564380C (zh) 2009-12-02
IS8192A (is) 2005-12-22
IL172923A0 (en) 2006-06-11
US7141568B2 (en) 2006-11-28
NO20060113L (no) 2006-04-05
AP2006003480A0 (en) 2006-02-28
ZA200600095B (en) 2007-01-31
IS2843B (is) 2013-08-15
BRPI0411868A (pt) 2006-08-08
PT1644376E (pt) 2010-09-24
SI1644376T1 (sl) 2010-11-30
US20050032839A1 (en) 2005-02-10
WO2005005427A1 (en) 2005-01-20
MY139072A (en) 2009-08-28
ES2349780T3 (es) 2011-01-11
AU2004255347B2 (en) 2010-04-08
MA28064A1 (fr) 2006-08-01
GEP20084395B (en) 2008-06-10
EA200600209A1 (ru) 2006-06-30
HN2004000232A (es) 2011-01-17
UA81682C2 (en) 2008-01-25
DOP2004000949A (es) 2005-01-15
JP2009513525A (ja) 2009-04-02
PL1644376T3 (pl) 2011-03-31
GT200400133A (es) 2005-04-18
CA2531759A1 (en) 2005-01-20
CR8171A (es) 2006-08-09
CN1820009A (zh) 2006-08-16
AP2214A (en) 2011-03-04
BRPI0411868B1 (pt) 2019-11-12
ECSP056246A (es) 2006-04-19
HK1089769A1 (en) 2006-12-08
TW200510385A (en) 2005-03-16
EA009462B1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
RS20060004A (en) Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
MY143206A (en) 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
CA2555262C (en) 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
PL1687305T3 (pl) Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
GB0330042D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
CU23566B7 (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa